Pink Sheet is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Crestor, Serevent Are Among Problem Drugs Cited By FDA Safety Reviewer

This article was originally published in The Pink Sheet Daily

Executive Summary

FDA Office of Drug Safety personnel will be publishing a paper on statins and rhabdomyolysis in an upcoming issue of the Journal of the American Medical Association, Associate Director for Science David Graham told the Senate Finance Committee during a Nov. 18 hearing on Merck's withdrawal of Vioxx

You may also be interested in...



AstraZeneca Determined To Validate Crestor Safety, Toprol XL Patent Protection

AstraZeneca is looking to epidemiological data to demonstrate Crestor's safety profile

AstraZeneca Determined To Validate Crestor Safety, Toprol XL Patent Protection

AstraZeneca is looking to epidemiological data to demonstrate Crestor's safety profile

Grassley Stumbles In Comments On Meridia’s Regulatory History

Finance Committee chair criticizes lack of action on the obesity agent, but Abbott revised the product’s risk management plan nearly a year ago.

Related Content

Topics

Latest News
See All
UsernamePublicRestriction

Register

PS058167

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel